Lantern Pharma Inc. cotiza a 0.74 USD y tiene una capitalización bursátil de $11M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of adva…
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | — | $-0.30 | $-0.36 | $-0.39 |
| Estimado | $-0.38 | $-0.36 | $-0.46 | $-0.47 |
| Sorpresa | — | +16.7% | +21.7% | +17.0% |
| Métrica | LTRN | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -262.0% | -40.4% | -221.6% |
| ROA | -155.1% | -32.0% | -123.1% |
| Current Ratio | 2.40 | 2.84 | -0.44 |
| Debt / Equity | — | 0.28 | — |